Importantly, recent work has shown that dasatinib (or other TKI) delivery to brain tumor parenchyma may be further improved by strategies to inhibit active efflux proteins (P-glycoprotein (P-gp) and breast cancer resistance protein (Bcrp1)). Here, ABCG2 is linked to brain neoplasm.